ArriVent BioPharma, Inc. (AVBP)
NASDAQ: AVBP · Real-Time Price · USD
30.04
-0.29 (-0.96%)
At close: Apr 28, 2026, 4:00 PM EDT
30.15
+0.11 (0.37%)
After-hours: Apr 28, 2026, 7:44 PM EDT
ArriVent BioPharma Employees
ArriVent BioPharma had 77 employees as of December 31, 2025. The number of employees increased by 25 or 48.08% compared to the previous year.
Employees
77
Change (1Y)
25
Growth (1Y)
48.08%
Revenue / Employee
n/a
Profits / Employee
-$2,159,844
Market Cap
1.33B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 77 | 25 | 48.08% |
| Dec 31, 2024 | 52 | 12 | 30.00% |
| Dec 31, 2023 | 40 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Iovance Biotherapeutics | 975 |
| Novavax | 749 |
| Wave Life Sciences | 317 |
| Viridian Therapeutics | 252 |
| Precigen | 160 |
| Maze Therapeutics | 141 |
| MapLight Therapeutics | 133 |
| Olema Pharmaceuticals | 131 |
AVBP News
- 6 weeks ago - ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting - GlobeNewsWire
- 7 weeks ago - ArriVent BioPharma Reports Full Year 2025 Financial Results - GlobeNewsWire
- 4 months ago - ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer - GlobeNewsWire
- 6 months ago - ArriVent BioPharma Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 7 months ago - ArriVent Appoints Brent S. Rice as Chief Commercial Officer - GlobeNewsWire
- 8 months ago - Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer - GlobeNewsWire
- 9 months ago - ArriVent BioPharma Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 10 months ago - ArriVent's Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026 - GlobeNewsWire